View Post

Sanofi’s, AstraZeneca’s and Radius’ oral SERDs could establish clinical worth in ER+ breast cancer by showing similar efficacy to Faslodex, experts say

In Clinical Studies News by Barbara Jacoby

By: Manasi Vaidyacl From: clinicaltrialsarena.com Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, AstraZeneca’s Faslodex (fulvestrant) or generic aromatase inhibitors in oestrogen receptor positive (ER+) HER2-negative breast cancer, said experts. Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, …